arrow_back Back to App

Freedom to Heal Act: Easier Access to Experimental Drugs for Patients.

This act simplifies access to experimental drugs for seriously ill patients who have exhausted other treatment options. Doctors will find it easier to register to administer these drugs, potentially accelerating treatment and offering hope to patients. It introduces new rules for doctors and drug manufacturers to ensure safety and control over substances.
Key points
Allows doctors to more easily obtain special authorization to administer experimental drugs, currently under strict control, to patients.
Patients with serious illnesses for whom standard treatments are ineffective may gain faster access to potentially life-saving therapies.
Establishes clear rules for doctors regarding the storage, administration, and documentation of experimental drugs to prevent misuse.
Specifies that doctors must meet certain conditions, such as relevant experience and manufacturer consent, to administer these therapies.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_3346
Sponsor: Sen. Booker, Cory A. [D-NJ]
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Freedom to Heal Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_3346.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What are the main provisions?

Key points include:

  • Allows doctors to more easily obtain special authorization to administer experimental drugs, currently under strict control, to patients.
  • Patients with serious illnesses for whom standard treatments are ineffective may gain faster access to potentially life-saving therapies.
  • Establishes clear rules for doctors regarding the storage, administration, and documentation of experimental drugs to prevent misuse.
  • Specifies that doctors must meet certain conditions, such as relevant experience and manufacturer consent, to administer these therapies.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Booker, Cory A. [D-NJ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-31.

CATEGORIES

Health Courts and Law